Growth & profitability
- Revenue has declined 47.0% per year over the past 5 years.
Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 1.9 years of cash runway.
ATNM Financials Actinium Pharmaceuticals, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $90000 | -$34M | 0.0% | -40274.4% | -$25M | — | $48M |
| 2024 | — | -$38M | — | — | -$33M | — | $73M |
| 2023 | $81000 | -$49M | 0.0% | -64098.8% | -$47M | — | $77M |
| 2022 | $1M | -$33M | 0.0% | -3311.1% | $8M | — | $109M |
| 2021 | $1M | -$25M | 21.3% | -2182.2% | -$21M | — | $78M |
| 2020 | — | -$22M | — | — | -$22M | — | $64M |
| 2019 | — | -$22M | — | — | -$22M | — | $9M |
| 2018 | — | -$24M | — | — | -$21M | — | $14M |
| 2017 | — | -$27M | — | — | -$22M | — | $17M |
| 2016 | — | -$24M | — | — | -$21M | — | $21M |
| 2015 | — | -$21M | — | — | -$19M | — | $26M |
| 2014 | — | -$25M | — | — | -$15M | — | $7M |
| 2014 | — | -$83M | — | — | -$54M | — | $6M |
| 2013 | — | -$11M | — | — | -$6M | — | $6M |
| 2013 | — | -$61M | — | — | -$50M | — | $4M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$6M | — | — | -$6M | — | $42M |
| Dec '25 | $0 | -$6M | — | — | — | — | $48M |
| Sep '25 | $90000 | -$5M | 0.0% | -6324.4% | — | — | $53M |
| Jun '25 | — | -$7M | — | — | — | — | $60M |
| Mar '25 | — | -$16M | — | — | — | — | $65M |
| Dec '24 | — | -$7M | — | — | -$6M | — | $73M |
| Sep '24 | — | -$12M | — | — | -$12M | — | $79M |
| Jun '24 | — | -$11M | — | — | -$8M | — | $86M |
| Mar '24 | — | -$9M | — | — | -$7M | — | $84M |
| Dec '23 | — | -$9M | — | — | -$7M | — | $77M |
| Sep '23 | — | -$13M | — | — | -$11M | — | $83M |
| Jun '23 | — | -$15M | — | — | -$14M | — | $91M |
| Mar '23 | — | -$11M | — | — | -$15M | — | $95M |
| Dec '22 | $0 | -$11M | — | — | -$8M | — | $109M |
| Sep '22 | $45000 | -$9M | 0.0% | -21775.6% | -$6M | — | $112M |
| Jun '22 | $45000 | -$8M | 0.0% | -17444.4% | $28M | — | $116M |
| Mar '22 | $940000 | -$5M | 0.0% | -549.4% | -$6M | — | $72M |
| Dec '21 | $23000 | -$8M | 0.0% | -34991.3% | -$5M | — | $78M |
| Sep '21 | $233000 | -$6M | 0.0% | -2776.4% | -$6M | — | $82M |
| Jun '21 | $266000 | -$5M | 0.0% | -1907.9% | -$5M | — | $82M |
Valuation over time
How the market has priced ATNM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 287.1× (Mar '23) to 331.9× (Jun '26).
P/S
Frequently asked questions
Is ATNM growing its revenue and profit?
Over the past 5 years, Actinium Pharmaceuticals, Inc.'s revenue has declined 47.0% per year. These are computed facts, not advice.
How much debt does ATNM have?
As of FY2025, Actinium Pharmaceuticals, Inc. reported — of total debt against $48M of cash.
What is ATNM's profit margin?
In FY2025, gross margin was —, operating margin -40274.4%, and net margin -37652.2%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.